To measure the degree of concordance of the results of the different HER-2
assays, the [kappa] statistic and its 95% confidence interval (95% CI) were calculated.
A FISH test for HER-2
/ neu recently became commercially available from Vysis Inc.
Only a few women in Santa Clarita with the HER-2
gene qualified to participate in the study, he said.
0 million in grants from the DOD in the development of its live Listeria vaccines directed against HER-2
for breast cancer and HMW-MAA, an antiangiogenic vaccine.
9 December 2011 - Generex Biotechnology Corp (PINK:GNBT) unveiled on Thursday positive data from its Phase II clinical trial of a new Ii-Key Hybrid-based HER-2
/neu Peptide Vaccine (AE37) in HER-2
expressing breast cancer patients.
protein, which is also known as c-erbB-2 or neu, is a member of subclass 1 of the superfamily of receptor tyrosine kinases.
Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced the publication of a paper entitled "Treatment of Mammary Carcinomas in HER-2
Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-like Receptor 9" in Clinical Cancer Research (2009, 15, 1575-84) co-authored by scientists from Idera and Merck & Co.
These molecules are able to bind to two validated tumour targets: HER-2
, which is present on aggressive breast tumours, and PDGFR-beta, which plays a significant role in angiogenesis associated with solid tumour growth and development.
It is used to treat patients with a gene mutation that results in too much of a protein known as HER-2
, which fuels the progression of the disease.
/neu or c-erbB-2) encodes an 185-kDa transmembrane glycoprotein that is a member of the type I family of growth factor receptors.
Abbott will provide ANGLE with its proprietary PathVysion HER-2
DNA FISH Probe kits for its ANG-002 US Food & Drug Administration (FDA) study for FISH (fluorescence in situ hybridisation) analysis of circulating tumour cells (CTCs) in the form of a research grant.
affects 25per cent of women and has a poor prognosis.